AI is Making Drug Discovery Easier
Including AI in Drug discovery can lower the hurdles and challenges which were previously faced by researchers and scientists.
FREMONT, CA: Researchers face slim odds while transforming molecules into medicines. The success rate of drug discovery even on an average scale dangles between a little higher and little lower, causing a sluggish growth in the development of new medicines. With failure rates of drug discovery elevating in the past decade, scientists and researchers have collectively concluded to integrate artificial intelligence (AI) to enhance and enrich the clinical trial process. AI, with its sophisticated computational tools such as molecular dynamics simulation and machine learning, has provided a positive response for creating better medicines.
Back in the day, a drug discovery usually started with basic research to uncover targets that are highly susceptible to infection. Then, the researchers dealt with a high throughput screening process to detect protein affinity. After that, came various complex chemical and biological tests to fine-tune the results, it sounds such an intricate and strenuous process. But including AI in all these steps efficiently will sharpen the effectiveness of each stage.
AI-powered tools are already being utilized in discovering upcoming drugs by clinical researchers. However, it is still to be seen how ready the healthcare sector is for this change.
AI-powered computational tools are being used to leverage extensive scale data for identifying better novel targets. The ability to harness knowledge and crucial information from genetic data for understanding diseases has been made possible by AI-powered tools.
Unraveling biological information from AI explained why drug trials often failed to succeed in Phase II and III trials. Creating a genotypic and phenotypic flowchart helps scientists to find superior starting targets and reduces the calculative errors.
Scientists repeatedly struggle while analyzing patients' data. However, with AI, the analysis of tens and thousands of individual data becomes an easy task to conduct. With machine learning, the researchers can focus on key things that further improve the functionality and efficiency of the clinical drug development process. Analyzing patient's data can detect and even identify the stage of a specific disease. Therefore, efficient data management by AI researchers can trigger perfect immune responses to eliminate the growing threats inside the body.
Press Releases : CIOReview
Event Partner : CIOReview
Media Partner : CIOReview
By Linda H. Butler, VP of Medical Affairs/CMO/CMIO, Rex...
By Laura Cruz, Global CIO, MDC Partners
By Greg Morrison, SVP & CIO, Cox Enterprises
By Lowell Gilvin, Chief Process Officer, Jabil
By Joe LaFeir, SVP, IS&S (Information Systems & Solutions),...
By Gerri Martin-Flickinger, CIO, Adobe Systems
By Aaron Weis, VP & CIO, Axalta Coating Systems
By Levon Hooks, CIO-Global Corporate Solutions, JLL
By Steve Bein, VP-GIS, Michael Baker International
By Sam Schoelen, Chief Information Technology Officer,...
By Georgios Kyriakopoulos, VP of Equity Research, SunTrust...
By David Sliter, VP & GM of Communications, Media &...
By Julie Stafford, SVP Strategic Consulting, Tangoe
By Dan Adam, CIO, Extreme Networks
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Aaron Gette, CIO, The Bay Club Company
By Dr. Volker G. Hildebrand, Global VP, SAP Hybris
By Meerah Rajavel, CIO, Forcepoint
By Philip Loftus, SVP IT & CIO, SSM Health
By Christy Hartner, SVP, Commerce Bank